Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression

Translational Oncology(2020)10.1016/j.tranon.2020.100751Source: DataRank Database

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression is a research paper published in Translational Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 26 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access26 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.97)OA: goldTopics (29)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Carrie Sun,Sijia Tao,Adeboye O. Osunkoya ORCID,Rebecca S. Arnold,John A. Petros ORCID

Live enrichment

PubMed:32199273 PMC:PMC7082632 OpenAlex:https://openalex.org/W3010662474

National Institutes of Health

Grant: 3P30CA138292-04S2

Winship Cancer Institute Cancer Center Support Grant

National Institutes of Health

Grant: 5P30CA138292-11

Winship Cancer Institute Cancer Center Support Grant

National Institutes of Health

Grant: 5U01CA217875-04

Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbation

National Institutes of Health

Grant: 5U01CA168449-04

High Throughput Protein-Protein Interaction Interrogation in Cancer

National Institutes of Health

FWCI

1.97

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.tranon.2020.100751

publisherhttps://doi.org/10.1016/j.tranon.2020.100751

publisherhttps://api.elsevier.com/content/article/PII:S1936523320301157?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1936523320301157?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32199273

Fields of Study

Prostate Cancer Treatment and ResearchUbiquitin and proteasome pathwaysMelanoma and MAPK Pathways0301 basic medicine03 medical and health sciences

Keywords

EnzalutamideLNCaPAndrogen receptorProstate cancerIn vivoCancer researchMAPK/ERK pathwayApoptosisAndrogenAndrogen deprivation therapyDocetaxelChemistryPharmacologyMedicineInternal medicineSignal transductionEndocrinologyBiologyCancerHormoneBiochemistryOriginal articleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282

Sustainable Development Goals

SDG 3: 3. Good health

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression

FAIR Checklist

Authors (8)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)